Tuberculosis is highly infectious and a global problem that Covid-19 has only made worse. Ironically, two legacies of our response to Covid-19 can give us hope. Many health systems now have unprecedentedly large testing and tracing infrastructures that we can use to test for TB.
The drug was developed by the non-profit TB Alliance. Some experts have said nonprofit organizations may provide a long-term solution to the growing problem of antibiotic resistance.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Emocha Managing Director Morad Elmi said he expects the company to add at least three more states by the end of the year.
Avisa Pharma is focusing primarily on tuberculosis detection, with aims to develop a rapid, point-of-care test that could determine if a patient has the disease within 10 minutes.
The startup's underlying research has been backed by the Gates Foundation since 2014.
The point-of-care diagnostics market is continuing to grow - blood testing and monitoring infectious diseases will be much more advanced.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company doesn't say much about its platform, but that it uses multiplexing technology to seek out specific proteins, nucleic acids and small molecules.
Drug-resistant tuberculosis could be a new epidemic concern.
Think Ebola patients are the only ones quarantined in the 21st century? People with other contagious diseases – like drug-resistant tuberculous – are kept in isolation as well. Natalie Shure describes her two years in solitary in a long essay Inconspicuous Consumption. (One warning: the introduction of this post is not safe for work and […]
What started as a Johns Hopkins Hospital program to train healthcare workers to treat HIV in Uganda has evolved into a multimedia platform for adherence, clinical trials and chronic diseases rolled into a healthcare startup, Emocha. In a presentation at DreamIt Health Baltimore’s demo day, CEO Sebastian Seiguer talked about the company’s origins at Johns […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
It’s been more than four decades since a new drug for tuberculosis has been approved by the FDA. Although Janssen is igniting hope with bedaquiline, which has been given priority review by the FDA and is set to begin late-stage trials this fall, there is still a great need for new ways to prevent and […]